Novel Cancer Vaccine Combined With Pembrolizumab Shows Promise in Metastatic Melanoma
Source: Targeted Oncology, August 2021
Combination treatment with the universal cancer vaccine, UV1, and the immune checkpoint inhibitor, pembrolizumab (Keytruda) showed strong signals of clinical response in patients with metastatic melanoma while also meeting its key safety/tolerability end point, according to findings announced in a press release by Ultimovacs ASA.1
